Proteins International

Rochester, MI 48063

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $0.0
First Award Date 04/01/85
Most Recent Award Date 05/01/90

Key Personnel

Last Name Name Awards Contact
Mahle Norma H Mahle 1
Sevilla Cynthia L Sevilla 6
Eliezer Naomi S Eliezer 2

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/90 - 10/31/90

A major problem in treatment of cataracts by extracapsular lens replacement is the subsequent loss of vision due to "secondary cataract" formation, or posterior capsule opacification. The economic impact of cataract surgery in the United States has been estimated to be $3.5 billion per year, and may reach $5.5 billion by the year 2008. Up to 5...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/90 - 05/31/91

Difunctional carbonyl compounds are toxic, mutagenic and carcinogenic and are ubiquitous contaminants of the human environment. The simplest examples of such compounds are malondialdehyde, acrolein and methyl glyoxal. Malondialdehyde is a product of lipid peroxidation and prostaglandin biosynthesis and is present in virtually all mammalian tis...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/10/89 - 01/31/90

Difunctional carbonyl compounds are toxic, mutagenic and carcinogenic and are ubiquitous contaminants of the human environment. The simplest examples of such compounds are malondialdehyde, acrolein and methyl glyoxal. Malondialdehyde is a product of lipid peroxidation and prostaglandin biosynthesis and is present in virtually all mammalian tis...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/10/88 - 11/30/88

The long-term objective of this project is the development and characterization of conjugates between plasminogen activators (urokinase, tissue plasminogen activator, single chain urokinase) and monoclonal antibodies specific for human cardiac heavy chain myosin. This type of conjugate by selectively targeting the plasminogen activator to damag...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/87 - 03/30/88

Difunctional carbonyl compounds are toxic, mutagenic and carcinogenic and are ubiquitous contaminants of the human environment. The simplest examples of such compounds are malondialdehyde, acrolein and methyl glyoxal. Malondialdehyde is a product of lipid peroxidation and prostaglandin biosynthesis and is present in virtually all mammalian tis...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/87 - 03/31/88

Progesterone receptor is one of a group of steroid hormone receptors that has been shown to have important regulatory effects in mammary and other target tissues. The qualitative and quantitative determination of progesterone receptor is useful in, for example, the therapeutic management of breast cancer. Currently, available assays for progest...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/86 - 07/31/87

Cellular components of the immune system, including cytotoxic T cells, macrophages and natural killer cells, are capable of the direct destruction of a variety of target cells including allogeneic cells and virus-infected or malignant cells within the host individual. Research on these cellular cytotoxicity reactions, their modulation in a vari...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/86 - 09/30/87

The long term objective of this project is the development and characterization of a conjugate between human urokinase and a monoclonal antibody specific for human fibrin. This complex should allow for enhanced plasminogen activation at the sites of fibrin clots while reducing systemic activation of plasminogen and the associated deleterious ef...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/85 - 03/31/86

The long term objective of this project is the development and characterization of a conjugate between human urokinase and a monoclonal antibody specific for human fibrin. This complex should allow for enhanced plasminogen activation at the sites of fibrin clots while reducing systemic activation of plasminogen and the associated deleterious ef...